RxDoctor Payments Data

Ramani Gosala, MD

Pulmonary Disease · East Stroudsburg, PANPI 1881836930

Payments from drug & device makers

$1,092in general payments, 2019–2025

Across 42 payments — averaging $26.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$239
  • AstraZeneca$198
  • Actelion Pharmaceuticals US, Inc.$160
  • Genentech USA, Inc.$146
  • Harmony Biosciences LLC$92
  • Amgen$60
  • plus $198 from 7 others

What the payments were for

  • Food & beverage$93085%
  • Education$16215%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,092 in reported general payments places this provider in the 45th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$119,843
Medicare patients
604
Services billed
1,399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter227$208,849
Breo ElliptaFluticasone/Vilanterol140$84,138
Dupixent PenDupilumab13$48,646
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$48,118
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr47$31,821
Arnuity ElliptaFluticasone Furoate35$13,357
Fluticasone-SalmeterolFluticasone Propion/Salmeterol72$11,815
Albuterol Sulfate HfaAlbuterol Sulfate369$10,551
Incruse ElliptaUmeclidinium Bromide27$9,639
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate46$9,166
SymbicortBudesonide/Formoterol Fumarate27$8,246
BreynaBudesonide/Formoterol Fumarate15$4,495
Wixela InhubFluticasone Propion/Salmeterol21$3,462
Varenicline Tartrate11$3,129
Ventolin HfaAlbuterol Sulfate45$2,927

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$239$347,803476 claims
AstraZenecaBreztri Aerosphere, Symbicort$198$56,36476 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in East Stroudsburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →